Abstract: A camsylate salt of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.

Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.

Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.

Abstract: Compositions and methods of selectively activating Akt3 are provided.

Abstract: A gold(III) complex of formula (I) or formula (II) wherein R1 and R2 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, or an optionally substituted aryl; R3 and R4 are each independently a hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted alkoxy, a hydroxyl, a halo, a nitro, a cyano, a N-monosubstituted amino group, or a N,N-disubstituted amino group; and X is Cl, Br, or I. A pharmaceutical composition containing the gold(III) complex of formula (I) or (II), and a method of treating cancer are included.

Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.

Abstract: An application of ellagic acid and a metabolic derivative urolithin compound thereof in preparation of an immunomodulatory medicine is provided. Classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis, neuromyelitis optica mouse model, ulcerative colitis, and skin transplantation, are used as examples to conduct experiments from various aspects and perspectives, such as neurological function scores, histopathological changes of lesions, inflammatory factor expression, and pro-inflammatory cell numbers.

Abstract: An electronically weakly coupled 4,4?-divinylazobenzene-bridged diruthenium complex bearing two Ru(CO)Cl(PiPr3)2 moieties, its synthesis, and its use as a catalyst in organic processes.

Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

Abstract: Disclosed herein are synthesis methods for coelenterazine. Also disclosed are articles including the coelenterazine and coelenterazine derivatives. Representative absorbent articles include disposable diapers and adult incontinence products.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.

Abstract: The present invention relates to a phenyl alkyl carbamate compound for use in preventing or treating neurodegenerative diseases. The phenyl alkyl carbamate compound of the present invention, prevented dopaminergic neuron loss, attenuated activation of astrocyte/microglia, repressed phosphorylated alpha-synuclein, and regulated phosphorylation levels of tau and acetylation levels of alpha-tubulin in the Parkinson's disease animal model. In addition, the phenyl alkyl carbamate compound of the present invention reduced the Amyloid-beta precursor protein and Amyloid-beta. Therefore, the phenyl alkyl carbamate compound of the present invention may be effectively used for preventing or treating neurodegenerative diseases.

Abstract: A method for preparing diazoxide includes reacting o-aminobenzenesulfonamide with N-chlorosuccinimide in a chlorine solvent to obtain 2-amino-5-chlorobenzenesulfonamide, mixing the 2-amino-5-chlorobenzenesulfonamide, an imidazole salt and an amide solvent, then heating same for reaction so as to obtain diazoxide; or mixing o-aminobenzenesulfonamide, an imidazole salt and an amide solvent, then heating same for reaction to obtain a compound IV; then reacting the compound IV with N-chlorosuccinimide in a chlorine solvent to obtain diazoxide. The application of imidazole hydrochloride as a catalyst in preparing diazoxide is also disclosed. The present invention avoids the use of highly corrosive and toxic chlorosulfonyl isocyanate, a strong acid (sulfuric acid), and a high reaction temperature (240-250° C.

Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.

Abstract: Ethylene oxide purification by quenching and washing ethylene oxide reactor effluent prior to passing the gaseous ethylene oxide-containing stream to an ethylene oxide absorber to form a dilute aqueous ethylene oxide and carbon dioxide solution and thereafter stripping that solution in an EO stripper to produce a gaseous ethylene oxide and carbon dioxide-containing overhead vapor which is then passed to a reabsorber wherein the ethylene oxide and part of the carbon dioxide vapors are absorbed to form an aqueous reabsorbate solution from which carbon dioxide is removed to produce an ethylene oxide-containing solution is improved by passing an impurities-containing liquid bleed stream obtained from the quench wash to a second, small quench bleed stripper where steam and carbon dioxide are added and gaseous overhead from that quench bleed stripper is passed to the reabsorber for recovery of the EO and removal of formaldehyde and other impurities.

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.